AU2001268103A1 - Amorphous oxazole coumpound and its use as cox-2 inhibitor - Google Patents

Amorphous oxazole coumpound and its use as cox-2 inhibitor

Info

Publication number
AU2001268103A1
AU2001268103A1 AU2001268103A AU6810301A AU2001268103A1 AU 2001268103 A1 AU2001268103 A1 AU 2001268103A1 AU 2001268103 A AU2001268103 A AU 2001268103A AU 6810301 A AU6810301 A AU 6810301A AU 2001268103 A1 AU2001268103 A1 AU 2001268103A1
Authority
AU
Australia
Prior art keywords
coumpound
cox
oxazole
amorphous
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268103A
Inventor
Daniel Korey
Thomas W. Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2001268103A1 publication Critical patent/AU2001268103A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2001268103A 2000-05-26 2001-05-25 Amorphous oxazole coumpound and its use as cox-2 inhibitor Abandoned AU2001268103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20717900P 2000-05-26 2000-05-26
US60207179 2000-05-26
PCT/US2001/017269 WO2001092238A1 (en) 2000-05-26 2001-05-25 Amorphous oxazole coumpound and its use as cox-2 inhibitor

Publications (1)

Publication Number Publication Date
AU2001268103A1 true AU2001268103A1 (en) 2001-12-11

Family

ID=22769505

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268103A Abandoned AU2001268103A1 (en) 2000-05-26 2001-05-25 Amorphous oxazole coumpound and its use as cox-2 inhibitor

Country Status (5)

Country Link
US (1) US20020032226A1 (en)
JP (1) JP2003535082A (en)
KR (1) KR20030007657A (en)
AU (1) AU2001268103A1 (en)
WO (1) WO2001092238A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004109053A2 (en) 2003-06-04 2004-12-16 Sun Drilling Products Corporation Lost circulation material blend offering high fluid loss with minimum solids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2636819B2 (en) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 Oxazole-based heterocyclic aromatic compounds
TW477789B (en) * 1998-09-03 2002-03-01 Japan Tobacco Inc Production method of oxazole compound

Also Published As

Publication number Publication date
KR20030007657A (en) 2003-01-23
JP2003535082A (en) 2003-11-25
US20020032226A1 (en) 2002-03-14
WO2001092238A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001292582A1 (en) C-nitroso compounds and use thereof
AU2001285409A1 (en) Memory devices and methods for use therewith
AU6383001A (en) Cache time determination
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001280599A1 (en) Compounds and methods
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001253418A1 (en) Compounds and methods
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2001233837A1 (en) Benzthiazoles as tnf and pde-iv inhibitors
AU2001243394A1 (en) Compounds and methods
AU2001292047A1 (en) Composition containing an azaphthalocyanine and use
AU7431901A (en) Coherence-free cache
AU2001248820A1 (en) Thiazole and oxazole derivatives
AU2001261750A1 (en) Laminate and its use
AU7458201A (en) Laminate and use thereof
AUPQ872300A0 (en) Compounds and methods
AU2001241498A1 (en) Matrix metalloproteinase inhibitors and uses thereof
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors